Literature DB >> 25472644

MicroRNA-29b is a Novel Prognostic Marker in Colorectal Cancer.

Akira Inoue1, Hirofumi Yamamoto2, Mamoru Uemura1, Junichi Nishimura1, Taishi Hata1, Ichiro Takemasa1, Masakazu Ikenaga3, Masataka Ikeda4, Kohei Murata5, Tsunekazu Mizushima1, Yuichiro Doki1, Masaki Mori1.   

Abstract

PURPOSE: Recent studies have suggested that microRNA-29 (miR-29) family members may play important roles in human cancer by regulating cell proliferation, differentiation, apoptosis, migration, and invasion. The present study aimed to investigate the clinical significance and biological function of miR-29b in colorectal cancer (CRC).
METHODS: Real-time polymerase chain reaction was used to quantify miR-29b expression. The association between miR-29b and survival was evaluated in 245 patients with CRC. We transfected an miR-29b mimetic into CRC cells to explore the functional role of miR-29b in vitro, based on a proliferation assay, flow cytometry, and Western blotting.
RESULTS: In clinical samples of CRC, miR-29b expression was significantly reduced in tumor tissues compared with normal mucosa (p < 0.012). Multivariate survival analyses indicated that miR-29b expression was an independent prognostic factor for disease-free survival (p = 0.026), lymph node metastasis (p = 0.004), and pathological T classification (p = 0.002). In a multivariate analysis of 5-year overall survival, we found a similar association between lymph node metastasis, pathological T classification, venous invasion, and miR-29b expression (p = 0.013). In vitro, low Ki-67-positive staining showed that administration of the mimic-miR-29b reduced proliferation of CRC cells. An Annexin V apoptosis assay and flow cytometric analysis revealed that miR-29b induced apoptosis and arrested the cell cycle at the G1/S transition. Moreover, miR-29b inhibited the expression of MCL1 and CDK6.
CONCLUSIONS: Our findings indicated that miR-29b may be a useful, novel, prognostic marker and may play important roles in regulating apoptosis and cell cycle in CRC.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25472644     DOI: 10.1245/s10434-014-4255-8

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   5.344


  18 in total

1.  Circulating levels of the miRNAs, miR-194, and miR-29b, as clinically useful biomarkers for colorectal cancer.

Authors:  Gholam Basati; Amirnader Emami Razavi; Iraj Pakzad; Fardin Ali Malayeri
Journal:  Tumour Biol       Date:  2015-08-29

2.  MicroRNA expression profiling in the colorectal normal-adenoma-carcinoma transition.

Authors:  Jian Li; Yunshi Zhong; Shilun Cai; Pinghong Zhou; Liqing Yao
Journal:  Oncol Lett       Date:  2019-06-10       Impact factor: 2.967

3.  LOC646329 long non-coding RNA sponges miR-29b-1 and regulates TGFβ signaling in colorectal cancer.

Authors:  Amir-Reza Javanmard; Sadat Dokanehiifard; Mehrdad Bohlooli; Bahram M Soltani
Journal:  J Cancer Res Clin Oncol       Date:  2020-02-07       Impact factor: 4.553

4.  Diagnostic Potential of Exosomal microRNAs in Colorectal Cancer.

Authors:  Jonas Dohmen; Alexander Semaan; Makbule Kobilay; Martin Zaleski; Vittorio Branchi; Anja Schlierf; Karina Hettwer; Steffen Uhlig; Gunther Hartmann; Jörg C Kalff; Hanno Matthaei; Philipp Lingohr; Stefan Holdenrieder
Journal:  Diagnostics (Basel)       Date:  2022-06-08

Review 5.  MicroRNAs as diagnostic and prognostic biomarkers in colorectal cancer.

Authors:  Rui Yi; Yao Li; Fei-Liang Wang; Gang Miao; Ruo-Mei Qi; Yan-Yang Zhao
Journal:  World J Gastrointest Oncol       Date:  2016-04-15

6.  MicroRNA-29 family inhibits rhabdomyosarcoma formation and progression by regulating GEFT function.

Authors:  Yang Wang; Liang Zhang; Yuweng Pang; Lingxie Song; Hao Shang; Zhenzhen Li; Qianqian Liu; Yangyang Zhang; Xiaomeng Wang; Qianru Li; Qiaochu Zhang; Chunxia Liu; Feng Li
Journal:  Am J Transl Res       Date:  2020-03-15       Impact factor: 4.060

Review 7.  MicroRNAs as growth regulators, their function and biomarker status in colorectal cancer.

Authors:  Lina Cekaite; Peter W Eide; Guro E Lind; Rolf I Skotheim; Ragnhild A Lothe
Journal:  Oncotarget       Date:  2016-02-09

8.  EZH2 expression is a prognostic biomarker in patients with colorectal cancer treated with anti-EGFR therapeutics.

Authors:  Itaru Yamamoto; Katsuhiko Nosho; Shinichi Kanno; Hisayoshi Igarashi; Hiroyoshi Kurihara; Keisuke Ishigami; Kazuya Ishiguro; Kei Mitsuhashi; Reo Maruyama; Hideyuki Koide; Hiroyuki Okuda; Tadashi Hasegawa; Yasutaka Sukawa; Kenji Okita; Ichiro Takemasa; Hiroyuki Yamamoto; Yasuhisa Shinomura; Hiroshi Nakase
Journal:  Oncotarget       Date:  2017-03-14

Review 9.  New Concepts in Cancer Biomarkers: Circulating miRNAs in Liquid Biopsies.

Authors:  Erika Larrea; Carla Sole; Lorea Manterola; Ibai Goicoechea; María Armesto; María Arestin; María M Caffarel; Angela M Araujo; María Araiz; Marta Fernandez-Mercado; Charles H Lawrie
Journal:  Int J Mol Sci       Date:  2016-04-27       Impact factor: 5.923

10.  Prognostic value of microRNAs in colorectal cancer: a meta-analysis.

Authors:  Song Gao; Zhi-Ying Zhao; Rong Wu; Yue Zhang; Zhen-Yong Zhang
Journal:  Cancer Manag Res       Date:  2018-04-30       Impact factor: 3.989

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.